Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Receivables (2023 - 2024)

AC Immune (ACIU) has disclosed Receivables for 2 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables fell 92.75% to $1.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 92.75% decrease, with the full-year FY2024 number at $1.3 million, down 92.66% from a year prior.
  • Receivables was $1.3 million for Q4 2024 at AC Immune, down from $17.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $17.4 million in Q4 2023 to a low of $1.3 million in Q4 2024.